In the wake of Gossamer Bio, Inc.'s (NASDAQ:GOSS) latest US$15m market cap drop, institutional owners may be forced to take severe actions

In This Article:

Key Insights

  • Institutions' substantial holdings in Gossamer Bio implies that they have significant influence over the company's share price

  • 52% of the business is held by the top 13 shareholders

  • Recent purchases by insiders

Every investor in Gossamer Bio, Inc. (NASDAQ:GOSS) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 72% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

And institutional investors endured the highest losses after the company's share price fell by 12% last week. This set of investors may especially be concerned about the current loss, which adds to a one-year loss of 86% for shareholders. Institutions or "liquidity providers" control large sums of money and therefore, these types of investors usually have a lot of influence over stock price movements. As a result, if the decline continues, institutional investors may be pressured to sell Gossamer Bio which might hurt individual investors.

Let's delve deeper into each type of owner of Gossamer Bio, beginning with the chart below.

Check out our latest analysis for Gossamer Bio

ownership-breakdown
NasdaqGS:GOSS Ownership Breakdown May 13th 2023

What Does The Institutional Ownership Tell Us About Gossamer Bio?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that Gossamer Bio does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Gossamer Bio, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
NasdaqGS:GOSS Earnings and Revenue Growth May 13th 2023

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. We note that hedge funds don't have a meaningful investment in Gossamer Bio. The Vanguard Group, Inc. is currently the company's largest shareholder with 8.3% of shares outstanding. Hillhouse Investment Management, Ltd. is the second largest shareholder owning 5.2% of common stock, and BlackRock, Inc. holds about 4.9% of the company stock. In addition, we found that Faheem Hasnain, the CEO has 4.9% of the shares allocated to their name.